title: Rise of iPSCs as a cell source for adoptive immunotherapy.
abstract: Adoptive T cell transfer is a potentially effective strategy for treating cancer and viral infections. However, previous studies of cancer immunotherapy have shown that T cells expanded in vitro fall into an exhausted state and, consequently, have limited therapeutic effect. One way to overcome this obstacle is to use induced pluripotent stem cells (iPSCs) as a cell source for making effector T cells. In recent years, there have been several reports on generating effector T cells suitable for adoptive immunotherapy. The reported findings suggest that using iPSC technology, it may be possible to stably derive large numbers of juvenile memory T cells targeted to cancers or viruses. In this review, we describe a strategy for applying iPSC technology to immunotherapy and the characteristics of T cells derived from iPSCs. We also discuss how these technologies can be applied clinically in the future.
authors: Shin Kaneko Laboratory, Department of Cell Growth and Differentiation, Center of iPS cell Research and Application (CiRA), Kyoto University, Kawaharacho 53, Shogoin, Sakyouku, Kyoto, 606-8507, Japan.
authors: Atsutaka
authors: A
authors: Minagawa
authors: Shin
authors: S
authors: Kaneko
mesh_terms: D002454:Cell Differentiation; D000939:Epitopes; D006801:Humans; D016219:Immunotherapy, Adoptive / Q000379:methods*; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*; D039904:Pluripotent Stem Cells / Q000166:cytology; D013601:T-Lymphocytes / Q000276:immunology / Q000637:transplantation
chemical_list: D000939:Epitopes